Deerfield Invests $160 Million in MannKind Corporation Business Wire NEW YORK -- July 1, 2013 Deerfield Management Company has entered into an agreement with MannKind Corporation (NASDAQ: MNKD) under which Mannkind may receive up to $160,000,000. This financing is designed to support the regulatory process and commercialization activities for Afrezza®, MannKind’s inhaled insulin product. Deerfield funded $40,000,000 at closing and will fund three additional $40,000,000 tranches as MannKind successfully completes its Phase III clinical trial, repays its outstanding 3.75% convertible notes and receives FDA approval for Afrezza®. “We are pleased to be able to support MannKind’s innovative efforts to advance the treatment of diabetes,” said James E. Flynn, General Partner at Deerfield. “Diabetes remains one of the most prevalent, fastest growing and most expensive diseases from a societal standpoint and efforts to fund more effective and more widely adopted therapies are essential.” About Deerfield Deerfield is a leading investment management firm, committed to advancing healthcare through investment, information and philanthropy. For more information, please visit www.deerfield.com Contact: Deerfield Management Company Karen Arnone, 212-922-1349 email@example.com
Deerfield Invests $160 Million in MannKind Corporation
Press spacebar to pause and continue. Press esc to stop.